Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Update on Statin Treatment in Patients with Neuropsychiatric Disorders

Avan, R, Sahebnasagh, A, Hashemi, J, Monajati, M, Faramarzi, F, Henney, NC, Montecucco, F, Jamialahmadi, T and Sahebkar, A (2021) Update on Statin Treatment in Patients with Neuropsychiatric Disorders. Life, 11 (12). ISSN 2075-1729

Update on Statin Treatment in Patients with Neuropsychiatric Disorders.pdf - Published Version
Available under License Creative Commons Attribution.

Download (655kB) | Preview


Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuropsychiatric disorders. In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of electronic databases. We also explored the adverse effects of these drugs to obtain insights into the benefits and risks associated with their use in the treatment of these disorders. Lipophilic statins (including simvastatin) because of better brain penetrance may have greater protective effects against MDD and schizophrenia. The significant positive effects of statins in the treatment of anxiety disorders without any serious adverse side effects were shown in numerous studies. In OCD, BD, and delirium, limitations, and contradictions in the available data make it difficult to draw conclusions on any positive effect of statins. The positive effects of simvastatin in autism disorders have been evaluated in only a small number of clinical trials. Although some studies showed positive effect of statins in some neuropsychiatric disorders, further prospective studies are needed to confirm this and define the most effective doses and treatment durations.

Item Type: Article
Uncontrolled Keywords: Science & Technology; Life Sciences & Biomedicine; Biology; Microbiology; Life Sciences & Biomedicine - Other Topics; statins; neuropsychiatric disorders; clinical trials; adverse effects; major depressive disorder; schizophrenia; anxiety; obsessive-compulsive disorder; bipolar disorder; delirium; autism spectrum disorders; MAJOR DEPRESSIVE DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; SEVERE MENTAL-ILLNESS; DOUBLE-BLIND; BIPOLAR DISORDER; NITRIC-OXIDE; CHOLESTEROL REDUCTION; ADJUNCTIVE TREATMENT; CYTOKINE ALTERATIONS
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: MDPI AG
Related URLs:
Date Deposited: 08 Feb 2022 10:34
Last Modified: 08 Feb 2022 10:45
DOI or ID number: 10.3390/life11121365
URI: https://researchonline.ljmu.ac.uk/id/eprint/16252
View Item View Item